User login
Key clinical point: A second dose of eptinezumab may be beneficial in patients with migraine who exhibit a suboptimal first-dose response.
Major finding: Percent change in monthly migraine days (MMD) over weeks 1-12 (PROMISE-1: odds ratio [OR] 0.97; P = .0001; PROMISE-2: OR 0.94; P < .0001) and change in 6-item Headache Impact Test total score (only PROMISE-2: OR 0.92; P = .027) were observed to be significant first-dose predictors of second-dose response.
Study details: This post hoc analysis included patients with migraine (episodic [n = 416; PROMISE-1] and chronic [n = 479; PROMISE-2]), suboptimal response (<50% reduction from baseline in MMD across weeks 1-12), and patient-reported outcome data at weeks 12 and 24.
Disclosures: The study was sponsored by Lundbeck LLC, USA. Some authors declared serving as consultants, advisory board members, or speakers for and receiving speaker honoraria from various sources, including Lundbeck. The other authors are current orformer employees of H. Lundbeck A/S or its subsidiary/contracted service provider.
Source: Schim JD et al. Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials. Headache. 2022 (May 6). Doi: 10.1111/head.14302
Key clinical point: A second dose of eptinezumab may be beneficial in patients with migraine who exhibit a suboptimal first-dose response.
Major finding: Percent change in monthly migraine days (MMD) over weeks 1-12 (PROMISE-1: odds ratio [OR] 0.97; P = .0001; PROMISE-2: OR 0.94; P < .0001) and change in 6-item Headache Impact Test total score (only PROMISE-2: OR 0.92; P = .027) were observed to be significant first-dose predictors of second-dose response.
Study details: This post hoc analysis included patients with migraine (episodic [n = 416; PROMISE-1] and chronic [n = 479; PROMISE-2]), suboptimal response (<50% reduction from baseline in MMD across weeks 1-12), and patient-reported outcome data at weeks 12 and 24.
Disclosures: The study was sponsored by Lundbeck LLC, USA. Some authors declared serving as consultants, advisory board members, or speakers for and receiving speaker honoraria from various sources, including Lundbeck. The other authors are current orformer employees of H. Lundbeck A/S or its subsidiary/contracted service provider.
Source: Schim JD et al. Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials. Headache. 2022 (May 6). Doi: 10.1111/head.14302
Key clinical point: A second dose of eptinezumab may be beneficial in patients with migraine who exhibit a suboptimal first-dose response.
Major finding: Percent change in monthly migraine days (MMD) over weeks 1-12 (PROMISE-1: odds ratio [OR] 0.97; P = .0001; PROMISE-2: OR 0.94; P < .0001) and change in 6-item Headache Impact Test total score (only PROMISE-2: OR 0.92; P = .027) were observed to be significant first-dose predictors of second-dose response.
Study details: This post hoc analysis included patients with migraine (episodic [n = 416; PROMISE-1] and chronic [n = 479; PROMISE-2]), suboptimal response (<50% reduction from baseline in MMD across weeks 1-12), and patient-reported outcome data at weeks 12 and 24.
Disclosures: The study was sponsored by Lundbeck LLC, USA. Some authors declared serving as consultants, advisory board members, or speakers for and receiving speaker honoraria from various sources, including Lundbeck. The other authors are current orformer employees of H. Lundbeck A/S or its subsidiary/contracted service provider.
Source: Schim JD et al. Likelihood of response with subsequent dosing for patients with migraine and initial suboptimal response with eptinezumab: A post hoc analysis of two placebo-controlled randomized clinical trials. Headache. 2022 (May 6). Doi: 10.1111/head.14302